Background
Methods
Study design
Patient population
Study objectives
Variables
Statistical analyses
Results
Patient demographics and baseline characteristics in the CKD population
CKD cohort | DKD | CKD + HF | DKD + HF | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No MRA | Spiro < 6 months | Spiro ≥ 6 months | No MRA | Spiro < 6 months | Spiro ≥ 6 months | No MRA | Spiro < 6 months | Spiro ≥ 6 months | No MRA | Spiro < 6 months | Spiro ≥ 6 months | |||||||||||||
n = 112,730 | n = 869 | n = 481 | n = 75,616 | N = 891 | N = 469 | N = 14,653 | N = 512 | N = 373 | N = 21,144 | N = 808 | N = 458 | |||||||||||||
Age, years | ||||||||||||||||||||||||
Mean (SD) | 58.4 | 56.8 | 57.2 | 61.5 | 59.4 | 58.8 | 66.7 | 62.0 | 62.6 | 65.5 | 63.5 | 63.4 | ||||||||||||
Median | 59.0 | 57.0 | 57.0 | 61.0 | 60.0 | 59.0 | 67.0 | 61.0 | 62.0 | 64.0 | 62.0 | 62.0 | ||||||||||||
Range | 18 to 83 | 19 to 83 | 21 to 83 | 18 to 83 | 21 to 83 | 23 to 83 | 18 to 83 | 22 to 83 | 22 to 83 | 18 to 83 | 27 to 83 | 32 to 83 | ||||||||||||
Male, n (%) | 62,284 | (55.3) | 403 | (46.4) | 224 | (46.6) | 44,790 | (59.2) | 508 | (57.0) | 286 | (61.0) | 8527 | (58.2) | 336 | (65.6) | 253 | (67.8) | 12,789 | (60.5) | 515 | (63.7) | 312 | (68.1) |
Physician specialty, n (%) | ||||||||||||||||||||||||
Primary care Physician | 21,585 | (19.1) | 122 | (14.0) | 72 | (15.0) | 13,203 | (17.5) | 129 | (14.5) | 40 | (8.5) | 1850 | (12.6) | 38 | (7.4) | 37 | (9.9) | 2228 | (10.5) | 72 | (8.9) | 30 | (6.6) |
Internal medicine | 24,512 | (21.7) | 146 | (16.8) | 80 | (16.6) | 15,970 | (21.1) | 157 | (17.6) | 94 | (20.0) | 2622 | (17.9) | 74 | (14.5) | 37 | (9.9) | 3533 | (16.7) | 126 | (15.6) | 75 | (16.4) |
Cardiology | 4160 | (3.7) | 26 | (3.0) | 20 | (4.2) | 2774 | (3.7) | 24 | (2.7) | 12 | (2.6) | 1103 | (7.5) | 41 | (8.0) | 19 | (5.1) | 1182 | (5.6) | 57 | (7.1) | 33 | (7.2) |
Nephrology | 26,862 | (23.8) | 251 | (28.9) | 154 | (32.0) | 18,608 | (24.6) | 298 | (33.4) | 169 | (36.0) | 2436 | (16.6) | 71 | (13.9) | 61 | (16.4) | 4646 | (22.0) | 150 | (18.6) | 85 | (18.6) |
Hospital | 11,941 | (10.6) | 120 | (13.8) | 67 | (13.9) | 9110 | (12.0) | 122 | (13.7) | 59 | (12.6) | 2744 | (18.7) | 137 | (26.8) | 122 | (32.7) | 4148 | (19.6) | 204 | (25.2) | 128 | (27.9) |
Other | 21,346 | (18.9) | 175 | (20.1) | 74 | (15.4) | 14,304 | (18.9) | 144 | (16.2) | 79 | (16.8) | 3563 | (24.3) | 135 | (26.4) | 87 | (23.3) | 4882 | (23.1) | 172 | (21.3) | 95 | (20.7) |
Unknown | 2324 | (2.1) | 29 | (3.3) | 14 | (2.9) | 1647 | (2.2) | 17 | (1.9) | 16 | (3.4) | 335 | (2.3) | 16 | (3.1) | 10 | (2.7) | 525 | (2.5) | 27 | (3.3) | 12 | (2.6) |
Previous use of steroidal MRAs | ||||||||||||||||||||||||
Spironolactone | 2949 | (2.6) | 0 | (0.0) | 0 | (0.0) | 2900 | (3.8) | 0 | (0.0) | 0 | (0.0) | 1774 | (12.1) | 0 | (0.0) | 0 | (0.0) | 3087 | (14.6) | 0 | (0.0) | 0 | (0.0) |
Eplerenone | 174 | (0.2) | 0 | (0.0) | 0 | (0.0) | 159 | (0.2) | 0 | (0.0) | 0 | (0.0) | 97 | (0.7) | 0 | (0.0) | 0 | (0.0) | 144 | (0.7) | 0 | (0.0) | 0 | (0.0) |
Medications, n (%) | ||||||||||||||||||||||||
Angiotensin II receptor blockers | 21,797 | (19.3) | 256 | (29.5) | 155 | (32.2) | 21,943 | (29.0) | 339 | (38.0) | 198 | (42.2) | 3036 | (20.7) | 125 | (24.4) | 89 | (23.9) | 5874 | (27.8) | 251 | (31.1) | 145 | (31.7) |
ACE inhibitors | 34,066 | (30.2) | 295 | (33.9) | 169 | (35.1) | 34,146 | (45.2) | 438 | (49.2) | 248 | (52.9) | 5445 | (37.2) | 223 | (43.6) | 151 | (40.5) | 9565 | (45.2) | 400 | (49.5) | 237 | (51.7) |
Renin inhibitors | 737 | (0.7) | 14 | (1.6) | 13 | (2.7) | 1052 | (1.4) | 25 | (2.8) | 17 | (3.6) | 116 | (0.8) | 7 | (1.4) | 2 | (0.5) | 343 | (1.6) | 19 | (2.4) | 8 | (1.7) |
β-blockers | 33,078 | (29.3) | 351 | (40.4) | 198 | (41.2) | 30,472 | (40.3) | 468 | (52.5) | 285 | (60.8) | 8297 | (56.6) | 316 | (61.7) | 225 | (60.3) | 13,715 | (64.9) | 531 | (65.7) | 321 | (70.1) |
Calcium- channel blockers | 24,880 | (22.1) | 308 | (35.4) | 177 | (36.8) | 22,904 | (30.3) | 377 | (42.3) | 215 | (45.8) | 4238 | (28.9) | 137 | (26.8) | 108 | (29.0) | 7493 | (35.4) | 279 | (34.5) | 175 | (38.2) |
Vasodilators | 11,115 | (9.9) | 164 | (18.9) | 117 | (24.3) | 12,443 | (16.5) | 233 | (26.2) | 123 | (26.2) | 3512 | (24.0) | 142 | (27.7) | 105 | (28.2) | 7228 | (34.2) | 259 | (32.1) | 162 | (35.4) |
Diuretics | 25,848 | (22.9) | 363 | (41.8) | 228 | (47.4) | 25,907 | (34.3) | 477 | (53.5) | 259 | (55.2) | 7291 | (49.8) | 313 | (61.1) | 227 | (60.9) | 12,900 | (61.0) | 580 | (71.8) | 320 | (69.9) |
Comorbidities, n (%) | ||||||||||||||||||||||||
Hypertension | 78,431 | (69.6) | 672 | (77.3) | 381 | (79.2) | 65,617 | (86.8) | 801 | (89.9) | 425 | (90.6) | 12,209 | (83.3) | 420 | (82.0) | 275 | (73.7) | 19,502 | (92.2) | 727 | (90.0) | 417 | (91.0) |
CVD | 14,518 | (12.9) | 133 | (15.3) | 72 | (15.0) | 15,907 | (21.0) | 224 | (25.1) | 96 | (20.5) | 7166 | (48.9) | 266 | (52.0) | 176 | (47.2) | 11,645 | (55.1) | 438 | (54.2) | 250 | (54.6) |
IHD | 14,234 | (12.6) | 115 | (13.2) | 70 | (14.6) | 17,319 | (22.9) | 221 | (24.8) | 89 | (19.0) | 6932 | (47.3) | 233 | (45.5) | 163 | (43.7) | 12,440 | (58.8) | 462 | (57.2) | 267 | (58.3) |
LVH | 3163 | (2.8) | 35 | (4.0) | 23 | (4.8) | 3150 | (4.2) | 75 | (8.4) | 31 | (6.6) | 2819 | (19.2) | 143 | (27.9) | 102 | (27.3) | 4632 | (21.9) | 198 | (24.5) | 110 | (24.0) |
Anemia | 23,359 | (20.7) | 241 | (27.7) | 110 | (22.9) | 21,008 | (27.8) | 240 | (26.9) | 126 | (26.9) | 5616 | (38.3) | 157 | (30.7) | 111 | (29.8) | 9710 | (45.9) | 289 | (35.8) | 168 | (36.7) |
Hyperkalemia | 3257 | (2.9) | 32 | (3.7) | 12 | (2.5) | 4496 | (5.9) | 37 | (4.2) | 18 | (3.8) | 1079 | (7.4) | 18 | (3.5) | 12 | (3.2) | 2671 | (12.6) | 61 | (7.5) | 28 | (6.1) |
Healthcare costs, $ | ||||||||||||||||||||||||
Mean | 18,160 | 23,803 | 21,729 | 24,659 | 28,455 | 24,404 | 53,565 | 53,905 | 46,850 | 66,119 | 54,849 | 55,348 | ||||||||||||
95% CI | 17,878 to 18,442 | 20,351 to 27,256 | 17,699 to 25,759 | 24,263 to 25,054 | 24,362 to 32,548 | 20,706 to 28,103 | 51,882 to 55,248 | 44,942 to 62,868 | 37,678 to 56,022 | 64,579 to 67,659 | 48,251 to 61,448 | 46,433 to 64,263 | ||||||||||||
SD | 48,268 | 51,857 | 44,981 | 55,491 | 62,246 | 40,763 | 103,912 | 103,231 | 90,084 | 114,247 | 95,549 | 97,083 | ||||||||||||
Median | 5720 | 8120 | 7558 | 10,059 | 11,758 | 12,535 | 19,661 | 20,854 | 16,934 | 29,288 | 25,929 | 24,633 | ||||||||||||
Time to first treatment, daysa | ||||||||||||||||||||||||
Mean | – | 167.6 | 52.7 | – | 177.8 | 53.0 | – | 139.1 | 55.2 | – | 146.2 | 54.6 | ||||||||||||
95% CI | – | 159.7 to 175.6 | 47.9 to 57.6 | – | 170.2 to 185.4 | 48.0 to 57.9 | – | 128.9 to 149.2 | 49.9 to 60.5 | – | 138.2 to 154.3 | 49.6 to 59.6 | ||||||||||||
SD | – | 119.1 | 54.5 | – | 115.3 | 54.7 | – | 117.4 | 52.4 | – | 11,116.8 | 52.5 | ||||||||||||
Median | – | 184.0 | 32.0 | – | 196.0 | 33.0 | – | 118.5 | 37.0 | – | 123.0 | 35.0 |
Initiation of steroidal MRAs in the CKD population
Predictors of steroidal MRA use in the CKD population
Independent variables | CKD | DKD | CKD + HF | DKD + HF | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Odds ratio | Confidence interval | P value | Odds ratio | Confidence interval | P value | Odds ratio | Confidence interval | P value | Odds ratio | Confidence interval | P value | |||||
Lower limit | Upper limit | Lower limit | Upper limit | Lower limit | Upper limit | Lower limit | Upper limit | |||||||||
Age, years (vs 18–34 years) | ||||||||||||||||
35–44 | 1.93 | 1.43 | 2.61 | < 0.0001 | 1.15 | 0.72 | 1.82 | 0.5666 | 0.82 | 0.50 | 1.34 | 0.4255 | 1.10 | 0.47 | 2.53 | 0.83 |
45–54 | 1.48 | 1.11 | 1.96 | 0.0075 | 1.01 | 0.66 | 1.55 | 0.9672 | 0.98 | 0.64 | 1.51 | 0.9423 | 1.31 | 0.60 | 2.85 | 0.50 |
55–64 | 1.31 | 0.99 | 1.73 | 0.0593 | 0.90 | 0.59 | 1.37 | 0.6131 | 0.70 | 0.46 | 1.06 | 0.0897 | 1.14 | 0.53 | 2.48 | 0.73 |
65+ | 0.95 | 0.71 | 1.27 | 0.7419 | 0.63 | 0.41 | 0.98 | 0.0381 | 0.40 | 0.27 | 0.61 | < 0.0001 | 0.80 | 0.37 | 1.74 | 0.58 |
Sex (vs male) | ||||||||||||||||
Female | 1.43 | 1.28 | 1.59 | < 0.0001 | 1.04 | 0.93 | 1.16 | 0.4554 | 0.77 | 0.66 | 0.89 | 0.0004 | 0.83 | 0.73 | 0.93 | 0.002 |
Prescribing physician specialty at inclusion (vs general/family practice) | ||||||||||||||||
Internal Medicine | 1.04 | 0.86 | 1.26 | 0.695 | 1.25 | 1.03 | 1.52 | 0.0266 | 1.03 | 0.77 | 1.39 | 0.8268 | 1.30 | 1.02 | 1.66 | 0.03 |
Cardiology | 1.28 | 0.93 | 1.75 | 0.126 | 1.11 | 0.78 | 1.59 | 0.5677 | 1.36 | 0.97 | 1.92 | 0.0789 | 1.79 | 1.34 | 2.40 | < 0.0001 |
Nephrology | 1.45 | 1.22 | 1.73 | < 0.0001 | 1.76 | 1.47 | 2.10 | < 0.0001 | 1.27 | 0.95 | 1.70 | 0.1068 | 1.11 | 0.88 | 1.41 | 0.38 |
Hospital | 1.69 | 1.38 | 2.07 | < 0.0001 | 1.49 | 1.21 | 1.85 | 0.0002 | 2.09 | 1.61 | 2.73 | < 0.0001 | 1.68 | 1.34 | 2.11 | < 0.0001 |
Other/unknown | 1.34 | 1.12 | 1.601 | 0.0017 | 1.24 | 1.02 | 1.51 | 0.0288 | 1.50 | 1.15 | 1.95 | 0.0027 | 1.30 | 1.03 | 1.63 | 0.02 |
Previous medication use (yes vs no) | ||||||||||||||||
ARBs | 1.75 | 1.55 | 1.97 | < 0.0001 | 1.62 | 1.44 | 1.82 | < 0.0001 | 1.40 | 1.19 | 1.65 | < 0.0001 | 1.34 | 1.18 | 1.52 | < 0.0001 |
ACE inhibitors | 1.24 | 1.10 | 1.39 | 0.0003 | 1.37 | 1.22 | 1.54 | < 0.0001 | 1.33 | 1.16 | 1.54 | < 0.0001 | 1.34 | 1.19 | 1.51 | < 0.0001 |
Renin inhibitors | 2.11 | 1.44 | 3.10 | 0.0001 | 1.66 | 1.21 | 2.27 | 0.0016 | 1.28 | 0.65 | 2.52 | 0.476 | 1.25 | 0.83 | 1.890 | 0.28 |
Vasodilators | 2.20 | 1.92 | 2.53 | < 0.0001 | 1.64 | 1.45 | 1.86 | < 0.0001 | 1.25 | 1.06 | 1.46 | 0.0066 | 0.97 | 0.85 | 1.09 | 0.59 |
Comorbidities
| ||||||||||||||||
LVH | 1.26 | 0.97 | 1.65 | 0.0884 | 1.71 | 1.39 | 2.09 | < 0.0001 | 1.71 | 1.46 | 2.000 | < 0.0001 | 1.28 | 1.11 | 1.46 | 0.0005 |
Anemia | 1.07 | 0.94 | 1.21 | 0.2916 | 0.84 | 0.74 | 0.95 | 0.0063 | 0.72 | 0.62 | 0.84 | < 0.0001 | 0.70 | 0.62 | 0.79 | < 0.0001 |
Edema | 2.14 | 1.85 | 2.47 | < 0.0001 | 2.09 | 1.83 | 2.38 | < 0.0001 | 1.48 | 1.26 | 1.73 | < 0.0001 | 1.47 | 1.30 | 1.66 | < 0.0001 |
Proteinuria | 1.18 | 1.00 | 1.41 | 0.0571 | 1.31 | 1.13 | 1.51 | 0.0004 | 0.82 | 0.59 | 1.15 | 0.2475 | 0.98 | 0.80 | 1.20 | 0.85 |
Hyperkalemia | 0.96 | 0.71 | 1.30 | 0.8046 | 0.55 | 0.42 | 0.73 | < 0.0001 | 0.49 | 0.34 | 0.70 | 0.0001 | 0.57 | 0.45 | 0.71 | < 0.0001 |
Sensitivity testing: c-statistic | 0.67 | 0.66 | 0.68 | 0.63 |
Concomitant medication use, incidence of clinical events and healthcare costs during follow-up
Concomitant medication use during follow-up
Clinical events during follow up
Characteristics | CKD | DKD | CKD + HF | DKD + HF | ||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No MRA | Spironolactone | No MRA < 6 months | Spironolactone | No MRA | Spironolactone | No MRA | Spironolactone | |||||||||||||||||
< 6 months | ≥ 6 months | < 6 months | < 6 months | < 6 months | ≥ 6 months | < 6 months | ≥ 6 months | |||||||||||||||||
(n = 112,730) | (n = 869) | (n = 481) | (n = 75,616) | (n = 891) | (n = 469) | (n = 14,653) | (n = 512) | (n = 373) | (n = 21,144) | (n = 808) | (n = 458) | |||||||||||||
Concomitant medications, n (%) | ||||||||||||||||||||||||
Angiotensin II receptor blockers | 23,232 | (20.6) | 293 | (33.7) | 163 | (33.9) | 22,675 | (30.0) | 365 | (41.0) | 194 | (41.4) | 2915 | (19.9) | 134 | (26.2) | 88 | (23.6) | 5402 | (25.5) | 248 | (30.7) | 134 | (29.3) |
ACE inhibitors | 33,843 | (30.0) | 322 | (37.1) | 145 | (30.1) | 33,084 | (43.8) | 435 | (48.8) | 221 | (47.1) | 5149 | (35.1) | 265 | (51.8) | 191 | (51.2) | 8486 | (40.1) | 447 | (55.3) | 232 | (50.7) |
Renin inhibitors | 671 | (0.6) | 18 | (2.1) | 9 | (1.9) | 889 | (1.2) | 23 | (2.6) | 13 | (2.8) | 99 | (0.7) | 8 | (1.6) | 0 | (0.0) | 245 | (1.2) | 18 | (2.2) | 9 | (2.0 |
β-blockers | 36,496 | (32.4) | 515 | (59.3) | 261 | (54.3) | 33,657 | (44.5) | 611 | (68.6) | 328 | (69.9) | 9176 | (62.6) | 434 | (84.8) | 323 | (86.6) | 14,537 | (68.8) | 706 | (87.4) | 406 | (88.6) |
Calcium-channel blockers | 29,305 | (26.0) | 417 | (48.0) | 217 | (45.1) | 26,359 | (34.9) | 477 | (53.5) | 253 | (53.9) | 4625 | (31.6) | 172 | (33.6) | 122 | (32.7) | 7820 | (37.0) | 351 | (43.4) | 169 | (36.9) |
Vasodilators | 12,863 | (11.4) | 263 | (30.3) | 126 | (26.2) | 14,483 | (19.2) | 349 | (39.2) | 168 | (35.8) | 3960 | (27.0) | 224 | (43.8) | 145 | (38.9) | 7827 | (37.0) | 405 | (50.1) | 223 | (48.7) |
Diuretics | 26,812 | (23.8) | 526 | (60.5) | 255 | (53.0) | 27,196 | (36.0) | 627 | (70.4) | 315 | (67.2) | 7647 | (52.2) | 432 | (84.4) | 302 | (81.0) | 13,023 | (61.6) | 714 | (88.4) | 385 | (84.1) |
Clinical events, n (%) | ||||||||||||||||||||||||
Reproductive system and breast disordersa | 10,517 | (9.3) | 78 | (9.0) | 59 | (12.3) | 7028 | (9.3) | 117 | (13.1) | 59 | (12.6) | 1032 | (7.0) | 39 | (7.6) | 29 | (7.8) | 1532 | (7.2) | 72 | (8.9) | 39 | (8.5) |
Hyperkalemia | 5187 | (4.6) | 94 | (10.8) | 53 | (11.0) | 6890 | (9.1) | 149 | (16.7) | 67 | (14.3) | 1593 | (10.9) | 78 | (15.2) | 53 | (14.2) | 3647 | (17.2) | 190 | (23.5) | 75 | (16.4) |
Stroke | 9821 | (8.7) | 120 | (13.8) | 42 | (8.7) | 9532 | (12.6) | 179 | (20.1) | 63 | (13.4) | 3249 | (22.2) | 125 | (24.4) | 78 | (20.9) | 5307 | (25.1) | 219 | (27.1) | 99 | (21.6) |
Myocardial infarction | 3440 | (3.1) | 59 | (6.8) | 26 | (5.4) | 3975 | (5.3) | 105 | (11.8) | 35 | (7.5) | 2185 | (14.9) | 118 | (23.0) | 90 | (24.1) | 4098 | (19.4) | 218 | (27.0) | 124 | (27.1) |
Heart failure | 3066 | (2.7) | 99 | (11.4) | 30 | (6.2) | 4418 | (5.8) | 203 | (22.8) | 39 | (8.3) | 11,274 | (76.9) | 470 | (91.8) | 351 | (94.1) | 16,511 | (78.1) | 765 | (94.7) | 425 | (92.8) |
Thrombosis | 3594 | (3.2) | 51 | (5.9) | 26 | (5.4) | 2708 | (3.6) | 58 | (6.5) | 28 | (6.0) | 1246 | (8.5) | 72 | (14.1) | 32 | (8.6) | 1834 | (8.7) | 89 | (11.0) | 39 | (8.5) |
Healthcare costs
Patient demographics and baseline characteristics in the MRA population
Variable | MRA cohort | |||||||
---|---|---|---|---|---|---|---|---|
CKD | DKD | CKD + HF | DKD + HF | |||||
(n = 1574) | (n = 1574) | (n = 1004) | (n = 1747) | |||||
Age, years | ||||||||
Mean (SD) | 56.1 (13.0) | 59.0 (10.6) | 62.7 (13.5) | 63.5 (10.7) | ||||
Median | 57.0 | 60.0 | 61.0 | 63.0 | ||||
Range | 19 to 83 | 22 to 83 | 22 to 83 | 28 to 83 | ||||
Men, n (%) | 747 | (47.5) | 925 | (58.8) | 671 | (66.8) | 1113 | (63.7) |
Physician specialty, n (%) | ||||||||
Primary care physician | 207 | (13.2) | 166 | (10.5) | 106 | (10.6) | 173 | (9.9) |
Internal medicine | 258 | (16.4) | 280 | (17.8) | 163 | (16.2) | 310 | (17.7) |
Cardiology | 48 | (3.0) | 37 | (2.4) | 94 | (9.4) | 128 | (7.3) |
Nephrology | 602 | (38.2) | 666 | (42.3) | 210 | (20.9) | 430 | (24.6) |
Hospital | 176 | (11.2) | 152 | (9.7) | 190 | (18.9) | 295 | (16.9) |
Other | 241 | (15.3) | 235 | (14.9) | 211 | (21.0) | 370 | (21.2) |
Unknown | 42 | (2.7) | 38 | (2.4) | 30 | (3.0) | 41 | (2.3) |
Medications, n (%) | ||||||||
Angiotensin II receptor blockers | 539 | (34.2) | 704 | (44.7) | 258 | (25.7) | 573 | (32.8) |
ACE inhibitors | 609 | (38.7) | 817 | (51.9) | 460 | (45.8) | 924 | (52.9) |
Renin inhibitors | 46 | (2.9) | 55 | (3.5) | 13 | (1.3) | 50 | (2.9) |
Β-blockers | 735 | (46.7) | 993 | (63.1) | 710 | (70.7) | 1366 | (78.2) |
Calcium-channel blockers | 722 | (45.9) | 817 | (51.9) | 321 | (32.0) | 766 | (43.8) |
Vasodilators | 395 | (25.1) | 529 | (33.6) | 351 | (35.0) | 789 | (45.2) |
Diuretics | 778 | (49.4) | 953 | (60.5) | 694 | (69.1) | 1390 | (79.6) |
Comorbidities, n (%) | ||||||||
Hypertension | 1391 | (88.4) | 1516 | (96.3) | 949 | (94.5) | 1696 | (97.1) |
CVD | 275 | (17.5) | 412 | (26.2) | 641 | (63.8) | 1145 | (65.5) |
IHD | 245 | (15.6) | 388 | (24.7) | 595 | (59.3) | 1212 | (69.4) |
LVH | 106 | (6.7) | 156 | (9.9) | 390 | (38.8) | 668 | (38.2) |
Anemia | 518 | (32.9) | 576 | (36.6) | 436 | (43.4) | 941 | (53.9) |
Hyperkalemia | 95 | (6.0) | 109 | (6.9) | 75 | (7.5) | 216 | (12.4) |
Healthcare costs, $ | ||||||||
Mean | 31,380 | 32,761 | 77,274 | 84,733 | ||||
95% CI | 28,275 to 34,485 | 29,995 to 35,527 | 69,997 to 84,551 | 79,324 to 90,141 | ||||
SD | 62,801 | 55,954 | 117,501 | 115,256 | ||||
Median | 11,944 | 16,185 | 38,447 | 48,117 |